AEHR

2x model: valuation-to-growth is 38.3/100 with convexity 75.0/100; that means the score is rewarding growth-adjusted asymmetry, not cheapness in isolation. 5x model: market-cap asymmetry is 100.0/100 at roughly $2.9B current market cap, which is why size matters more here than business quality alone.

The earnings/growth score is driven by reported fundamentals, not narrative. revenue growth -43.7%, gross margin 30.7%, operating margin -41.0%, profit margin -25.2%, FCF margin -16.5%. Component support: growth acceleration 20.5, survivability 57.6.

Aehr's catalyst is reliability testing for more complex power and AI-adjacent devices. The thesis is not that Aehr is already a large AI winner; it is that a small supplier can re-rate violently if customers decide its wafer-level test systems are necessary for higher-volume advanced devices.

Technical setup comes from price action, not opinion: 20-day return -0.8%, 60-day return 128.0%, 120-day return 273.2%, 60-day relative strength vs QQQ 106.6%, 1-year max drawdown -42.3%, distance from 52-week high -17.6%, 60-day annualized volatility 134.9%. Above 50dma: True; above 200dma: True.

For June this pillar is better read as options/positioning confirmation, not social-media fluff. ATM implied volatility 136.8%, call/put OI 0.7, call/put volume 1.2, OTM call OI share 34.9%, short % float 16.1%, short ratio 1.4. Component support: options asymmetry 69.5, squeeze bonus 3.0.

The base Goldilox math is roughly $2.9B today versus a $7.5B bull case, or about 2.58x. That is not a full 5x base case. Aehr tops the 5x list because its small size, volatility, and order-cycle optionality create a credible stretch case if a new demand cycle materializes.